1-3 of 3
Donna Acampora
Close
Sort by
Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4440–4441.
https://doi.org/10.1182/blood-2022-160204
Published: 2022
Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Nicole Watts, Barry Paul, Saurabh Chhabra, Neha Korde, Xhevahire Begic, David M Foureau, David J. Chung, Mauricio Pineda-Roman, Brinda Koya, Cindy Varga, Jing Ai, Natonya Daniels, Sarah Norek, Sara A Sutton, Michelle B Anderson, Ashley N Jewell, Paul W Eldridge, Donna Acampora, James T Symanowski, Luciano J. Costa, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4393–4395.
https://doi.org/10.1182/blood-2022-160071
Published: 2022
Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-138485
Published: 2020